Skip to main content

Kurma Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

84
Companies
$1.9B
Total invested
$24.3M
Avg. check
24
Industries
Health Care 17Biotechnology 16Medical 10Therapeutics 5Pharmaceutical 5Health Diagnostics 3+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 84
Axithra
September 2023

Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.

Biotechnology · Genk$10.7M Seed
Synendos Therapeutics
September 2025

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders.

Health Care · AllschwilGrant
EvlaBio
July 2025

EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.

Biotechnology · Zürich$24.6M Seed
Asceneuron
July 2024

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Biotechnology · Lausanne$100.0M Series C
Spotlight Medical
July 2024

Spotlight Medical develops AI tests to revolutionize cancer treatment, providing everyone with the best possible chance to beat cancer.

Artificial Intelligence (AI) · Paris$6.8M Seed
Minoryx Therapeutics
July 2025

Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.

Biotechnology · Barcelona$31.5M Grant
FeetMe
June 2024

FeetMe is a digital health company that provides a technology platform for in-clinic and real-world gait and activity assessments.

Fitness · ParisSeries B
Ermium Therapeutics
June 2022

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases.

Biotechnology · Paris$6.3M Series A
Vico Therapeutics
June 2024

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health Care · Leiden$12.3M Series B
Elkedonia
June 2025

Elkedonia is a biotech company dedicated to transforming antidepressant therapy.

Biotechnology · Strasbourg$12.9M Seed
Memo Therapeutics
May 2024

Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.

Biotechnology · Schlieren$22.0M Series C
Nuclidium
May 2026

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Health Care · Basel$33.6M Series B
Tacalyx
April 2026

Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.

Biotechnology · Berlin$12.9M Seed
DeepUll
April 2025

DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.

Biotechnology · Barcelona$56.9M Series C
Poppins
April 2025

We digitize music therapy into engaging products for accessible technologies.

EdTech · Paris$5.7M Venture - Series Unknown
Brink Therapeutics
April 2025

Brink Therapeutics is a Biotechnology Research firm conducting cell therapy research using reprogrammed recombinases.

Biotechnology · Paris$4.0M Seed
Laigo Bio
March 2026

Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.

Biotechnology · Utrecht$6.4M Seed
Charles.co
March 2026

Charles helps men regain control over their daily health concerns by starting with their personal health.

Fitness · Paris$297K Secondary Market
Safe Orthopaedics
March 2024

Safe Orthopaedics is a France-based company principally engaged in the medical devices industry.

Health Care · Californië$929K Post-IPO Debt
Step Pharma
February 2026

Step Pharma is a biotechnology company.

Biotechnology · Paris$2.9M Grant
Vivet Therapeutics
February 2024

Vivet Therapeutics is a biotechnology company developing gene therapy treatments for orphan diseases.

Biopharma · Paris$5.3M Grant
Adcytherix
October 2025

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

Biotechnology · Marseille$122.4M Series A
Sunrise
September 2025

We are a virtual sleep clinic, using our own 3-gram sensor to diagnose sleep with gold standard quality.

Health Care · Brussels$29.4M Venture - Series Unknown
Nuevocor
May 2025

Nuevocor operates as a preclinical-stage biotech company.

Biopharma · Singapore$45.0M Series B

Where Kurma Partners invests

Health Care17
Biotechnology16
Medical10
Therapeutics5
Pharmaceutical5
Health Diagnostics3

About Kurma Partners's portfolio

How many companies has Kurma Partners invested in?

Kurma Partners has invested in 84 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Kurma Partners invest in?

Kurma Partners's top investment sectors include Health Care, Biotechnology, Medical, Therapeutics, Pharmaceutical. The firm invests across 24 different industry categories.

What is Kurma Partners's largest investment?

Among tracked funding rounds, Adcytherix received $122.4M in a Series A round. Kurma Partners's total known invested capital is $1.9B.

What is the average investment size for Kurma Partners?

Kurma Partners's average investment size is $24.3M across its portfolio of 84 companies.

What are Kurma Partners's most recent investments?

Recent Kurma Partners portfolio additions include Axithra, Synendos Therapeutics, EvlaBio, Asceneuron, Spotlight Medical. These companies were founded in 2020 or later.

Reach the founders behind these 84 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →